Atossa Genetics Inc. (ATOS) Dive to All-Time Low

June 29, 2018 - By Sarah Holford

Atossa Genetics Inc. (NASDAQ:ATOS) Corporate Logo

Atossa Genetics Inc. (NASDAQ:ATOS) touched all time low on Jun, 29 touching $2.21. Our target is $2.06. announced it. The company has $6.22 million market cap. The company’s valuation will be $435,470 less at $2.06 target.

Ticker’s shares touched $2.21 during the last trading session after 3.07% change.Atossa Genetics Inc. has volume of 123,725 shares. Since June 29, 2017 ATOS has declined 41.40% and is downtrending. ATOS underperformed the S&P 500 by 53.97%.

Investors expect Atossa Genetics Inc. (NASDAQ:ATOS)’s quarterly earnings on August, 13., Faxor reports. Last year’s EPS was $-7.68, while now analysts expect change of 90.36 % up from current $-0.74 EPS. After $-0.71 EPS report previous quarter, Wall Street now sees 4.23 % negative EPS growth of Atossa Genetics Inc..

Atossa Genetics Inc. (NASDAQ:ATOS) Ratings Coverage

In total 2 analysts cover Atossa Genetics (NASDAQ:ATOS). “Buy” rating has 2, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 2 are the (NASDAQ:ATOS)’s analyst reports since January 26, 2018 according to StockzIntelligence Inc. The company rating was initiated by Maxim Group on Friday, January 26.

For more Atossa Genetics Inc. (NASDAQ:ATOS) news published briefly go to:,,, or The titles are as follows: “Atossa Genetics Appoints Two Additional Prominent Industry Executives to Strategic Advisory Board” published on June 14, 2018, “Your Daily Pharma Scoop: Reata Begins New Trial, CytoDyn Amends Protocol, Argenx Reports Positive Data” on June 22, 2018, “Benzinga’s Daily Biotech Pulse: Biohaven Sells Right To Drug, Obseva To Sell Shares” with a publish date: June 19, 2018, “Atossa Genetics (ATOS) Announces Opening of Phase 2 Study of Topical Endoxifen to Treat Mammographic Breast …” and the last “Benzinga’s Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos” with publication date: June 29, 2018.

Atossa Genetics Inc. a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States.The firm is worth $6.22 million. The firm is conducting a Phase II clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in-situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen for post-breast cancer and preventative therapy, as well as a potential therapy for breast density and other breast health conditions.Last it reported negative earnings. It offers ForeCYTE Breast Aspirator and FullCYTE Breast Aspirator, which collects specimens of nipple aspirate fluid for cytological testing at a laboratory; and a transport kit to assist with the packaging and transport of NAF samples to a laboratory, as well as makes and sells various medical devices primarily consisting of tools to assist breast surgeons.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.